Results for trodelvy
Trodelvy confirmed as the standard therapy for pre-treated metastatic breast cancer (XRAY)
A new study has confirmed that Trodelvy provides the best outcomes for patients with pretreated metastatic breast cancer. The new data support past studies identifingTrodelvy as the standard therapy.
Trodelvy helps with certain metastatic breast cancer | FORCE (XRAY) Breast - Treatment
Trodelvy (sacituzumab govitecan) improved progression-free survival in people with metastatic ER/PR-positive, HER2-negative breast cancer.
Trodelvy ayuda a tratar ciertos tipos de cáncer de mama metastásico | FORCE (XRAY)
Trodelvy (sacituzumab govitecán) mejoró la supervivencia sin progresión en personas con cáncer de mama metastásico ER+/PR+ y HER2-.
The FDA approved a new treatment for metastatic triple-negative breast cancer (XRAY) Breast - Treatment
The FDA approved a new drug to treat triple-negative metastatic breast cancer. The drug, known as Trodelvy is approved for use in people whose cancer did not respond or progressed after two previous lines of treatment.